vs
Amphastar Pharmaceuticals, Inc.（AMPH）与Ribbon Communications Inc.（RBBN）财务数据对比。点击上方公司名可切换其他公司
Amphastar Pharmaceuticals, Inc.的季度营收约是Ribbon Communications Inc.的1.1倍（$183.1M vs $162.6M），Ribbon Communications Inc.净利率更高（54.8% vs 13.3%，领先41.4%），Amphastar Pharmaceuticals, Inc.同比增速更快（-1.8% vs -10.3%），过去两年Amphastar Pharmaceuticals, Inc.的营收复合增速更高（3.2% vs -8.1%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
睿宾通信公司（Ribbon Communications Inc.）主要为电信运营商、企业及关键基础设施领域提供软件、IP与光网络解决方案。公司于2017年由Genband与Sonus Networks合并成立，总部位于美国得克萨斯州普莱诺，是一家上市科技企业。
AMPH vs RBBN — 直观对比
营收规模更大
AMPH
是对方的1.1倍
$162.6M
营收增速更快
AMPH
高出8.5%
-10.3%
净利率更高
RBBN
高出41.4%
13.3%
两年增速更快
AMPH
近两年复合增速
-8.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $162.6M |
| 净利润 | $24.4M | $89.1M |
| 毛利率 | 46.8% | 42.9% |
| 营业利润率 | 19.4% | 37.6% |
| 净利率 | 13.3% | 54.8% |
| 营收同比 | -1.8% | -10.3% |
| 净利润同比 | -35.7% | — |
| 每股收益（稀释后） | $0.51 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHRBBN
| Q1 26 | — | $162.6M | ||
| Q4 25 | $183.1M | $227.3M | ||
| Q3 25 | $191.8M | $215.4M | ||
| Q2 25 | $174.4M | $220.6M | ||
| Q1 25 | $170.5M | $181.3M | ||
| Q4 24 | $186.5M | $251.4M | ||
| Q3 24 | $191.2M | $210.2M | ||
| Q2 24 | $182.4M | $192.6M |
净利润AMPHRBBN
| Q1 26 | — | $89.1M | ||
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $-12.1M | ||
| Q2 25 | $31.0M | $-11.1M | ||
| Q1 25 | $25.3M | $-26.2M | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | $-13.4M | ||
| Q2 24 | $37.9M | $-16.8M |
毛利率AMPHRBBN
| Q1 26 | — | 42.9% | ||
| Q4 25 | 46.8% | 53.3% | ||
| Q3 25 | 51.4% | 50.1% | ||
| Q2 25 | 49.6% | 49.6% | ||
| Q1 25 | 50.0% | 45.4% | ||
| Q4 24 | 46.5% | 55.7% | ||
| Q3 24 | 53.3% | 52.1% | ||
| Q2 24 | 52.2% | 50.8% |
营业利润率AMPHRBBN
| Q1 26 | — | 37.6% | ||
| Q4 25 | 19.4% | 4.1% | ||
| Q3 25 | 13.2% | 1.3% | ||
| Q2 25 | 24.2% | 1.9% | ||
| Q1 25 | 21.9% | -10.8% | ||
| Q4 24 | 24.2% | 13.2% | ||
| Q3 24 | 29.8% | -0.4% | ||
| Q2 24 | 30.3% | -1.0% |
净利率AMPHRBBN
| Q1 26 | — | 54.8% | ||
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | -5.6% | ||
| Q2 25 | 17.8% | -5.0% | ||
| Q1 25 | 14.8% | -14.5% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | -6.4% | ||
| Q2 24 | 20.8% | -8.7% |
每股收益（稀释后）AMPHRBBN
| Q1 26 | — | $0.50 | ||
| Q4 25 | $0.51 | $0.50 | ||
| Q3 25 | $0.37 | $-0.07 | ||
| Q2 25 | $0.64 | $-0.06 | ||
| Q1 25 | $0.51 | $-0.15 | ||
| Q4 24 | $0.74 | $0.05 | ||
| Q3 24 | $0.78 | $-0.08 | ||
| Q2 24 | $0.73 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $67.6M |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $419.1M |
| 总资产 | $1.6B | — |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHRBBN
| Q1 26 | — | $67.6M | ||
| Q4 25 | $282.8M | $96.4M | ||
| Q3 25 | $276.2M | $74.8M | ||
| Q2 25 | $231.8M | $60.5M | ||
| Q1 25 | $236.9M | $71.2M | ||
| Q4 24 | $221.6M | $87.8M | ||
| Q3 24 | $250.5M | $37.2M | ||
| Q2 24 | $217.8M | $64.6M |
总债务AMPHRBBN
| Q1 26 | — | — | ||
| Q4 25 | $608.7M | $342.1M | ||
| Q3 25 | $608.6M | $344.3M | ||
| Q2 25 | $607.7M | $346.5M | ||
| Q1 25 | $603.9M | $347.4M | ||
| Q4 24 | $601.6M | $348.3M | ||
| Q3 24 | $596.4M | $349.1M | ||
| Q2 24 | $586.9M | $350.0M |
股东权益AMPHRBBN
| Q1 26 | — | $419.1M | ||
| Q4 25 | $788.8M | $449.0M | ||
| Q3 25 | $776.7M | $360.1M | ||
| Q2 25 | $757.5M | $370.4M | ||
| Q1 25 | $751.3M | $381.8M | ||
| Q4 24 | $732.3M | $404.6M | ||
| Q3 24 | $727.7M | $395.5M | ||
| Q2 24 | $713.3M | $405.0M |
总资产AMPHRBBN
| Q1 26 | — | — | ||
| Q4 25 | $1.6B | $1.2B | ||
| Q3 25 | $1.7B | $1.1B | ||
| Q2 25 | $1.6B | $1.1B | ||
| Q1 25 | $1.6B | $1.1B | ||
| Q4 24 | $1.6B | $1.2B | ||
| Q3 24 | $1.5B | $1.1B | ||
| Q2 24 | $1.5B | $1.1B |
负债/权益比AMPHRBBN
| Q1 26 | — | — | ||
| Q4 25 | 0.77× | 0.76× | ||
| Q3 25 | 0.78× | 0.96× | ||
| Q2 25 | 0.80× | 0.94× | ||
| Q1 25 | 0.80× | 0.91× | ||
| Q4 24 | 0.82× | 0.86× | ||
| Q3 24 | 0.82× | 0.88× | ||
| Q2 24 | 0.82× | 0.86× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | — |
| 自由现金流经营现金流 - 资本支出 | $24.6M | — |
| 自由现金流率自由现金流/营收 | 13.4% | — |
| 资本支出强度资本支出/营收 | 4.5% | — |
| 现金转化率经营现金流/净利润 | 1.35× | — |
| 过去12个月自由现金流最近4个季度 | $121.2M | — |
8季度趋势，按日历期对齐
经营现金流AMPHRBBN
| Q1 26 | — | — | ||
| Q4 25 | $32.9M | $29.2M | ||
| Q3 25 | $52.6M | $26.5M | ||
| Q2 25 | $35.6M | $-795.0K | ||
| Q1 25 | $35.1M | $-3.5M | ||
| Q4 24 | $29.0M | $61.8M | ||
| Q3 24 | $60.0M | $-14.8M | ||
| Q2 24 | $69.1M | $-9.8M |
自由现金流AMPHRBBN
| Q1 26 | — | — | ||
| Q4 25 | $24.6M | $27.3M | ||
| Q3 25 | $47.2M | $21.0M | ||
| Q2 25 | $25.0M | $-6.5M | ||
| Q1 25 | $24.4M | $-15.7M | ||
| Q4 24 | $16.6M | $53.8M | ||
| Q3 24 | $46.2M | $-23.7M | ||
| Q2 24 | $63.1M | $-12.9M |
自由现金流率AMPHRBBN
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | 12.0% | ||
| Q3 25 | 24.6% | 9.7% | ||
| Q2 25 | 14.3% | -2.9% | ||
| Q1 25 | 14.3% | -8.7% | ||
| Q4 24 | 8.9% | 21.4% | ||
| Q3 24 | 24.1% | -11.3% | ||
| Q2 24 | 34.6% | -6.7% |
资本支出强度AMPHRBBN
| Q1 26 | — | — | ||
| Q4 25 | 4.5% | 0.9% | ||
| Q3 25 | 2.8% | 2.6% | ||
| Q2 25 | 6.1% | 2.6% | ||
| Q1 25 | 6.3% | 6.7% | ||
| Q4 24 | 6.7% | 3.2% | ||
| Q3 24 | 7.2% | 4.2% | ||
| Q2 24 | 3.3% | 1.6% |
现金转化率AMPHRBBN
| Q1 26 | — | — | ||
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
RBBN
| Service | $94.5M | 58% |
| Product | $68.1M | 42% |
